Anavex Life Sciences (AVXL) - 2024 Q4 - Annual Report

Research and Development Expenses 69 | --- | --- | --- | --- | --- | |---------------------------------------|-----------------------|-----------------------------------------|----------------------------------------------------|---------------------------------| | | Number of Options | Weighted Average Exercise Price ($) | Weighted Average Grant Date Fair Value ($) | Aggregate intrinsic value ($) | | Outstanding, October 1, 2022 | 13,169,616 | 6.61 | 4.96 | 62,267,309 | | Granted | 1,959,000 | 9.30 | 6.60 ...